SG11202012624RA - Cyclic dinucleotides as sting agonists - Google Patents

Cyclic dinucleotides as sting agonists

Info

Publication number
SG11202012624RA
SG11202012624RA SG11202012624RA SG11202012624RA SG11202012624RA SG 11202012624R A SG11202012624R A SG 11202012624RA SG 11202012624R A SG11202012624R A SG 11202012624RA SG 11202012624R A SG11202012624R A SG 11202012624RA SG 11202012624R A SG11202012624R A SG 11202012624RA
Authority
SG
Singapore
Prior art keywords
sting agonists
cyclic dinucleotides
dinucleotides
cyclic
sting
Prior art date
Application number
SG11202012624RA
Other languages
English (en)
Inventor
Stuart Emanuel
Mark Richter
Peter J Connolly
James P Edwards
Guangyi Wang
Santhosh Kumar Thatikonda
Leonid Beigelman
Gilles Bignan
Wim Bert Griet Schepens
Marcel Viellevoye
Johannes Wilhelmus J F Thuring
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of SG11202012624RA publication Critical patent/SG11202012624RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11202012624RA 2018-07-17 2019-07-16 Cyclic dinucleotides as sting agonists SG11202012624RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862699001P 2018-07-17 2018-07-17
PCT/IB2019/056075 WO2020016782A1 (en) 2018-07-17 2019-07-16 Cyclic dinucleotides as sting agonists

Publications (1)

Publication Number Publication Date
SG11202012624RA true SG11202012624RA (en) 2021-02-25

Family

ID=67999987

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202012624RA SG11202012624RA (en) 2018-07-17 2019-07-16 Cyclic dinucleotides as sting agonists

Country Status (20)

Country Link
US (2) US11597746B2 (zh)
EP (1) EP3823976A1 (zh)
JP (1) JP2021531277A (zh)
KR (1) KR20210033026A (zh)
CN (1) CN112424212A (zh)
AR (1) AR122240A1 (zh)
AU (1) AU2019304230B2 (zh)
BR (1) BR112021000693A2 (zh)
CA (1) CA3106602A1 (zh)
EA (1) EA202190298A1 (zh)
EC (1) ECSP21003171A (zh)
IL (1) IL280105A (zh)
MA (1) MA53178A (zh)
MX (1) MX2021000625A (zh)
PE (1) PE20211636A1 (zh)
PH (1) PH12020552172A1 (zh)
SG (1) SG11202012624RA (zh)
TW (1) TW202030199A (zh)
UY (1) UY38304A (zh)
WO (1) WO2020016782A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020006290A (es) * 2017-12-15 2020-12-03 Janssen Biotech Inc Dinucleotidos ciclicos como agonistas de sting.
TW202030199A (zh) * 2018-07-17 2020-08-16 美商健生生物科技公司 作為ｓｔｉｎｇ促效劑之環狀二核苷酸
EP4134098A4 (en) 2020-04-10 2024-05-15 Ono Pharmaceutical Co CANCER THERAPY METHODS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX363780B (es) * 2015-12-03 2019-04-03 Glaxosmithkline Ip Dev Ltd Dinucleótidos de purina cíclica como moduladores del estimulador de los genes de interferón.
US10723756B2 (en) * 2016-01-11 2020-07-28 Innate Tumor Immunity Inc. Cyclic dinucleotides for treating conditions associated with STING activity such as cancer
WO2017123669A1 (en) * 2016-01-11 2017-07-20 Gary Glick Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
BR112018068748B1 (pt) 2016-03-18 2024-01-16 The Board Of Regents Of The University Of Texas System Composto dinucleotídeo cíclico, composição farmacêutica, e, uso de um composto
IL264049B2 (en) * 2016-07-06 2023-11-01 Sperovie Biosciences Inc Compounds, preparations and methods for treating the disease
WO2018045204A1 (en) * 2016-08-31 2018-03-08 Ifm Therapeutics, Inc Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity
JOP20170188A1 (ar) * 2016-11-25 2019-01-30 Janssen Biotech Inc ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
TW202030199A (zh) * 2018-07-17 2020-08-16 美商健生生物科技公司 作為ｓｔｉｎｇ促效劑之環狀二核苷酸

Also Published As

Publication number Publication date
CN112424212A (zh) 2021-02-26
UY38304A (es) 2020-01-31
JP2021531277A (ja) 2021-11-18
IL280105A (en) 2021-03-01
TW202030199A (zh) 2020-08-16
AU2019304230B2 (en) 2023-08-31
US20230287034A1 (en) 2023-09-14
EA202190298A1 (ru) 2021-04-16
EP3823976A1 (en) 2021-05-26
PE20211636A1 (es) 2021-08-24
PH12020552172A1 (en) 2021-06-07
AR122240A1 (es) 2022-08-31
US20210277046A1 (en) 2021-09-09
BR112021000693A2 (pt) 2021-04-13
MX2021000625A (es) 2021-03-25
ECSP21003171A (es) 2021-02-26
MA53178A (fr) 2021-05-26
CA3106602A1 (en) 2020-01-23
AU2019304230A1 (en) 2021-01-14
KR20210033026A (ko) 2021-03-25
US11597746B2 (en) 2023-03-07
WO2020016782A1 (en) 2020-01-23

Similar Documents

Publication Publication Date Title
HK1249109A1 (zh) 作為sting激動劑的環狀二核苷酸化合物
EP3621624A4 (en) CYCLIC DINUCLEOTIDIC COMPOUNDS AS STING AGONISTS
HK1250032A1 (zh) 作為sting調節劑的環狀嘌呤二核苷酸
ZA201904311B (en) Cyclic dinucleotides as sting (stimulator of interferon genes) agonists
IL260427B (en) Circular dinucleotides for the treatment of conditions related to sting activity such as cancer
EP3558324A4 (en) CYCLIC STING DINUCLEOTID AGONISTS FOR CANCER TREATMENT
EP3727401A4 (en) CYCLIC DINUCLEOTIDE COMPOUNDS USED AS STING AGONISTS
EP3774765A4 (en) Aza-benzothiophene compounds as sting agonists
ZA201802451B (en) 2,4-dihydroxy-nicotinamides as apj agonists
PL3233882T3 (pl) Fluorowane cykliczne dinukleotydy do indukcji cytokin
EP3255230A4 (en) Reciprocating device
IL280105A (en) Cyclic dinucleotides as STING agonists
HUE058662T2 (hu) Ciklikus dinukleotidok mint rákellenes szerek
ZA202106629B (en) Macrocyclic compounds as sting agonists
EP3873484C0 (en) NEW STING AGONISTS
EP3891166A4 (en) CYCLIC DI-NUCLEOTIDE COMPOUNDS USED AS STING AGONISTS
GB201910188D0 (en) Analyser
EP3891164A4 (en) CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
EP3891165A4 (en) CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
GB2577835B (en) Double-filtration laminar-flow single-use isolator
EP3612541A4 (en) CYCLIC PLASMENYLETHANOLAMINES
GB201717244D0 (en) Cherry I